CureVac N.V. Form 6-K (Feb. 4, 2021) — CV8102
Summary
A Form 6-K Report of Foreign Private Issuer furnished by CureVac N.V., Commission File Number 001-39446, for the month of February 2021. It states that on February 4, 2021, the Company issued a press release announcing an expansion of the ongoing Phase 1 study of its lead RNA-based cancer drug candidate, CV8102. The report states that the information in the Form 6-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. It is signed /s/ by Franz-Werner Haas, Chief Executive Officer.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“CureVac N.V. Form 6-K (Feb. 4, 2021) — CV8102.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2021-02-04-0001104659-21-011927-598297ca00/
, SHA-256 46fc40d8f2da12c5a45e6d9f9f2191f5934cdd84d1c2d06b8970f748ecc57d0c.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number 001-39446 CureVac N.V. Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: FORM 20-F x FORM 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: YES ¨ NO x If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______ On February 4, 2021, CureVac N.V. (the “Company”) issued a press release announcing that the Company started an expansion of the ongoing Phase 1 study with its lead RNA-based cancer drug candidate, CV8102. The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: February 4, 2021 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated February 4, 2021.
File and source
- File
- SEC_CVAC_6-K_filed2021-02-04_0001104659-21-011927.htm
- Size
- 12,811 bytes
- SHA-256
- 46fc40d8f2da12c5a45e6d9f9f2191f5934cdd84d1c2d06b8970f748ecc57d0c
- Original
- www.sec.gov